http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/list Mynewsdesk nyhetsfeed direkt från källan http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/list http://www.mynewsdesk.com/images/redesign/graphics/logos/logo-small.png 128 23 sv 15 Wed, 02 Nov 2011 09:01:24 +0100 Läkemedelsföretaget Sanofi presenterar idag Diabetesrapporten 2011. Den visar på stora regionala skillnader i måluppfyllelsen mellan olika landsting. Rapporten visar också att endast var fjärde av landets patienter som behandlas med tabletter och insulin når det uppsatta blodsockervärdet. För högt långtidsblodsocker (HbA1c) ökar risken för hjärtinfarkt, stroke samt dialyskrävande njursjukdom. http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/oekad-risk-foer-allvarliga-komplikationer-naer-svenskar-med-diabetes-faar-allt-saemre-blodsockervaerden-699825?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/oekad-risk-foer-allvarliga-komplikationer-naer-svenskar-med-diabetes-faar-allt-saemre-blodsockervaerden-699825?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease sanofi-aventis Tue, 27 Sep 2011 13:15:51 +0200 Europeisk förskrivarinformation har uppdaterats för att säkerställa att MULTAQ® används till lämpliga patienter med paroxysmalt och persisterande förmaksflimmer. CHMP vid EMA har bekräftat att en positiv nytto-riskbalans för MULTAQ® kvarstår vid behandling av en begränsad population av patienter med paroxysmalt och persisterande förmaksflimmer, efter sin granskning i enlighet med EMA:s artikel 20. http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/europeiska-laekemedelsmyndigheten-ema-bekraeftar-positiv-bedoemning-av-nytto-riskbalansen-foer-multaq-r-686769?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/europeiska-laekemedelsmyndigheten-ema-bekraeftar-positiv-bedoemning-av-nytto-riskbalansen-foer-multaq-r-686769?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease sanofi-aventis Tue, 06 Sep 2011 15:05:54 +0200 Over 2012-2015, Sanofi expects to deliver sales growth of at least 5% on average and higher business EPS growth. Growth platforms and Genzyme expected to provide more than 80% of Group sales in 2015. Solid progress on R&D transformation with the potential to launch 19 projects by end of 2015. http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/sanofi-announces-new-long-term-objectives-678268?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/sanofi-announces-new-long-term-objectives-678268?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease sanofi-aventis Wed, 22 Jun 2011 08:35:23 +0200 Sanofi announced today that it has entered into a global agreement with Medco Health Solutions, Inc. and United BioSource Corporation, a wholly owned subsidiary of Medco, to better leverage the real-world evidence generated during product development and throughout the product lifecycle in order to improve the overall quality of patient care. http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/sanofi-establishes-a-global-agreement-with-medco-and-ubc-to-improve-quality-of-patient-care-through-real-world-evidence-653782?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/sanofi-establishes-a-global-agreement-with-medco-and-ubc-to-improve-quality-of-patient-care-through-real-world-evidence-653782?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease sanofi-aventis Tue, 31 May 2011 09:41:48 +0200 Sanofi announced today that new results from a Phase III study showed that the investigational product Lyxumia® (lixisenatide), when used as an add-on therapy to basal insulin (in association with or without metformin), achieved its primary efficacy endpoint of significantly reducing HbA1c versus placebo for patients with type 2 diabetes without significantly increasing their risk of hypoglycemia. http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/sanofi-getgoal-program-on-lyxumia-r-as-an-add-on-to-basal-insulin-shows-significant-positive-phase-iii-results-642715?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/sanofi-getgoal-program-on-lyxumia-r-as-an-add-on-to-basal-insulin-shows-significant-positive-phase-iii-results-642715?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease sanofi-aventis Mon, 30 May 2011 11:21:51 +0200 Sanofi and Drugs for Neglected Diseases initiative (DNDi) announced today a three-year research collaboration agreement for the research of new treatments for nine neglected tropical diseases (NTDs), listed by the World Health Organization (WHO) for which new, adapted, and efficient tools are urgently needed to treat patients in endemic countries. http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/sanofi-and-dndi-drugs-for-neglected-diseases-initiative-sign-an-innovative-agreement-to-generate-new-drugs-for-neglected-tropical-diseases-642184?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/sanofi-and-dndi-drugs-for-neglected-diseases-initiative-sign-an-innovative-agreement-to-generate-new-drugs-for-neglected-tropical-diseases-642184?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease sanofi-aventis Thu, 19 May 2011 14:59:40 +0200 Sanofi today announced that data from eight compounds in the company’s robust oncology portfolio will be showcased in more than 100 abstracts at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 3-7, 2011. http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/data-at-asco-showcase-sanofi-s-commitment-to-research-and-identify-treatments-for-cancer-patients-636547?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/data-at-asco-showcase-sanofi-s-commitment-to-research-and-identify-treatments-for-cancer-patients-636547?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease sanofi-aventis Mon, 09 May 2011 14:07:33 +0200 Lauren Dousset är nu landschef på sanofi-aventis i Sverige och efterträder därmed Margarita Lopez Acosta. Sanofi-aventis är ett av världens största forskande läkemedelsföretag och fokuserar bland annat på onkologi, diabetes och hjärt-kärlsjukdomar. http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/laurent-dousset-aer-ny-landschef-paa-sanofi-aventis-i-sverige-629855?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/laurent-dousset-aer-ny-landschef-paa-sanofi-aventis-i-sverige-629855?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease sanofi-aventis Wed, 04 May 2011 11:09:39 +0200 Den 1 maj 2011 sänker vi kraftigt priset på Insuman Basal SoloSTAR vilket innebär att Insuman Basal SoloSTAR blir 20% billigare än Insulatard FlexPen. Därmed blir Insuman Basal SoloSTAR blir det billigaste NPH-insulinet i förfylld penna på den svenska marknaden. http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/nu-blir-insuman-basal-solostar-det-billigaste-nph-insulinet-i-foerfylld-penna-626805?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/nu-blir-insuman-basal-solostar-det-billigaste-nph-insulinet-i-foerfylld-penna-626805?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease sanofi-aventis Mon, 02 May 2011 14:09:12 +0200 http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/ny-studie-visar-paa-en-signifikant-minskning-av-antalet-skov-per-aar-och-uppbromsning-av-sjukdomsprogressen-hos-ms-patientersom-byter-till-copaxone-r-625449?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/ny-studie-visar-paa-en-signifikant-minskning-av-antalet-skov-per-aar-och-uppbromsning-av-sjukdomsprogressen-hos-ms-patientersom-byter-till-copaxone-r-625449?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease sanofi-aventis Tue, 12 Apr 2011 11:29:59 +0200 Sanofi-aventis announced today that lixisenatide, a once-daily GLP-1 receptor agonist under development for people with Type 2 diabetes, achieved its primary efficacy objective of significant HbA1c reduction and improved glycemic control from baseline versus placebo. The top-line results also showed that people treated with lixisenatide had a significant decrease in body weight. http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/lixisenatide-significantly-reduces-hba1c-without-increasing-hypoglycemia-in-patients-uncontrolled-on-sulfonylureas-615239?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/lixisenatide-significantly-reduces-hba1c-without-increasing-hypoglycemia-in-patients-uncontrolled-on-sulfonylureas-615239?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease sanofi-aventis Mon, 04 Apr 2011 11:27:55 +0200 EU-kommissionen har nu godkänt Jevtana (cabazitaxel), i kombination med prednison eller prednisolon, för behandling av patienter med metastatisk hormonrefraktär prostatacancer (mHRPC) som tidigare fått docetaxel-baserad behandling. Resultat från TROPIC-studien visade att Jevtana ger mer än hälften av patienterna åtminstone ett år till att leva. http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/jevtana-r-har-godkaents-som-andrahandsbehandling-av-framskriden-prostatacancer-foersta-preparatet-som-signifikant-foerlaenger-total-oeverlevnad-609969?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/jevtana-r-har-godkaents-som-andrahandsbehandling-av-framskriden-prostatacancer-foersta-preparatet-som-signifikant-foerlaenger-total-oeverlevnad-609969?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease sanofi-aventis Mon, 21 Mar 2011 09:24:01 +0100 Sanofi-aventis will donate 1 million Euros to support the aid relief efforts of the Japan Red Cross through the Sanofi Espoir Foundation for the Tohoku Pacific Earthquake and Tsunami that struck the area on March 11, 2011. Additionally, an appeal for generosity has been launched across all countries and affiliates worldwide, inviting employees who wish to join in this solidarity effort. http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/sanofi-aventis-and-its-employees-donate-to-tohoku-pacific-earthquake-relief-fund-600986?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/sanofi-aventis-and-its-employees-donate-to-tohoku-pacific-earthquake-relief-fund-600986?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease sanofi-aventis Wed, 09 Mar 2011 14:02:32 +0100 Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today it had signed a new agreement to donate $25 million, extending its decade-long partnership with the World Health Organization (WHO) for another five years to control neglected tropical diseases, including the potentially fatal Human African Trypanosomiasis, also known as sleeping sickness. http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/sanofi-aventis-signs-new-agreement-with-the-world-health-organization-who-to-fight-neglected-tropical-diseases-594370?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/sanofi-aventis-signs-new-agreement-with-the-world-health-organization-who-to-fight-neglected-tropical-diseases-594370?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease sanofi-aventis Wed, 26 Jan 2011 16:07:40 +0100 CHMP inom EMA har gett ett positivt utlåtande (”positive opinion”) där de rekommenderar att JEVTANA® (cabazitaxel) ska godkännas för försäljning inom EU. Rekommendationen gäller JEVTANA® i kombination med prednison eller prednisolon, och avser behandling av patienter med metastatisk hormonrefraktär prostatacancer (mHRPC) som tidigare fått docetaxel-baserad behandling. http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/nytt-cancerlaekemedel-mot-prostatacancer-rekommenderas-foer-godkaennande-inom-eu-570495?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/nytt-cancerlaekemedel-mot-prostatacancer-rekommenderas-foer-godkaennande-inom-eu-570495?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease sanofi-aventis Tue, 21 Dec 2010 16:03:32 +0100 Sanofi-aventis and Ascendis Pharma announced today a global licensing and patent transfer agreement on Ascendis’ proprietary TransCon Linker and Hydrogel carrier technology, which allows for a drug compound to be released in the body in a precise, time-controlled fashion, creating a long-acting effect. http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/sanofi-aventis-acquires-from-ascendis-pharma-worldwide-rights-on-drug-delivery-technology-in-diabetes-and-related-disorders-549070?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/sanofi-aventis-acquires-from-ascendis-pharma-worldwide-rights-on-drug-delivery-technology-in-diabetes-and-related-disorders-549070?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease sanofi-aventis Tue, 14 Dec 2010 15:06:52 +0100 Stora regionala skillnader, brist på urologer och kunskapsluckor skapar en orättvis cancervård i Sverige. Det slog en enig debatt fast vid ett kvällsseminarium i Stockholm. Samtidigt visade panelen att det finns en stark vilja att förändra vården och skapa bättre förutsättningar för alla att få tillgång till god och kvalitativ vård. http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/svensk-cancervaard-aer-inte-raettvis-544322?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/svensk-cancervaard-aer-inte-raettvis-544322?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease sanofi-aventis Tue, 14 Dec 2010 14:57:48 +0100 Sanofi-aventis is pleased to announce the appointment of Dr. Elias Zerhouni as President, Global Research & Development, covering Medicines and Vaccines, effective January 1, 2011. Dr. Zerhouni will report directly to Christopher A. Viehbacher, Chief Executive Officer of sanofi-aventis, and join the Executive Committee and the Management Committee. http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/sanofi-aventis-appoints-dr-elias-zerhouni-president-global-research-development-544314?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/sanofi-aventis-appoints-dr-elias-zerhouni-president-global-research-development-544314?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease sanofi-aventis Thu, 28 Oct 2010 16:55:50 +0200 http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/resilient-sales-and-business-eps-in-q3-2010-506932?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/resilient-sales-and-business-eps-in-q3-2010-506932?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease sanofi-aventis Mon, 18 Oct 2010 09:19:39 +0200 Sanofi-aventis announced today a research collaboration with Harvard University. The goal of the collaboration is to advance knowledge in the area of human health through basic and applied research and to promote scientific exchange between Harvard University and sanofi-aventis. The focus is translational biomedical research in multiple therapeutic areas such as cancer, diabetes and inflammation. http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/sanofi-aventis-establishes-research-collaboration-with-harvard-university-497897?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/se/pressroom/sanofi-aventis/pressrelease/view/sanofi-aventis-establishes-research-collaboration-with-harvard-university-497897?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease sanofi-aventis